Zarkadi Eirini

Medical Doctor

doctor

Education

2007: Graduation from 8th Lyceum of Patras (Graduation Mark 19.5/20)
2007: Admission in the Department of Medicine of the University of Patras, after successful participation in the Greek General National Examinations.
2007-2014: Student at the Department of Medicine of the University of Patras, Grade 6.51/10
21/4/2015-8/3/2016: Resident Doctor at the Department of Internal Medicine, General Hospital of Zakynthos
31/10/2016-30/3/2021: Resident Doctor at the Department of Pulmonary Medicine, General University Hospital of Patras
14/12/2020: Online Modules: Thoracic Training Programme, Part 1, European Respiratory Society
04/09/2021: Date of Acquisition of HERMES – Adult Diploma

Professional Experience

2011-2014: Supervising Assistant at the Customers & Sales Services Department of the Hellenic Telecommunications Company, Patras, Greece
21/4/2015-8/3/2016: Resident Doctor at the Department of Internal Medicine, General Hospital of Zakynthos
31/10/2016-30/3/2021: Resident Doctor at the Department of Pulmonary Medicine, General University Hospital of Patras
2/11/2021-today: Pulmonary Medicine, General University Hospital of Patras

Foreign Languages

  • English, Certificate of Proficiency in English, University of Cambridge, (2004)
  • Italian, Certificato Di Conoscenza Della Lingua Italiana, Livello B2, Celi 3 (2006)
  • Greek, Native Speaker

Computer Skills

  • Windows 10, Word, Excel, Powerpoint
  • Web Services

E-Posters In Conferences

  • “Organizing Pneumonia in a patient with ulcerative colitis under mesalazine treatment”, 26th Panhellenic Pulmonary Congress (Athens, 2017)
  • “Orgabuzubg Pneumonia in a patient with reticulonodular radiological pattern”, 26th Panhellenic Pulmonary Congress (Athens, 2017)
  • “interesting radiologial pattern in a patient with pulmonery sarcoidosis”, 27th Panhellenic Pulmonary Congress (Athens, 2018)
  • “Case report: Cryptogenic Organizing Pneumonia in a patient with antisynthetase syndrome-ASS”, 27th Panhellenic Pulmonary Congress (Athens, 2018)
  • “High Red Cell Distribution (RDW) as a possible negative prognostic factor in Pulmonary Embolism”, 29th Panhellenic Pulmonary Congress (Athens, 2020)
  • “The effect of the first lockdown in Bronchoscopic Laboratory in General University Hospital of Patras”, 29th Panhellenic Pulmonary Congress (Athens, 2020)
  • “Invasive Pulmonary Aspergillosis from Aspergillus niger in a patient with esiphageal cancer”, 29th Panhellenic Pulmonary Congress (Athens, 2020)
  • “Pulmonary embolism in a patient with hydatidosis”, 29th Panhellenic Pulmonary Congress (Athens, 2020)
  • “Safete and effectiveness of mycophenolate mofetil in interstitial lung desease”, ERS Virtual International Congress 2021
  • “Myositis associated-ILD: Radiologic features, immunity background and outcome”, 30th Panhellenic Pulmonary Congress (Athens, 2021)
  • “Safete and effectiveness of mycophenolate mofetil in interstitial lung desease: Data from machine learning software system”, 30th Panhellenic Pulmonary Congress (Athens, 2021)

Oral Anouncements In Conferences

  • “Pneumonia secondary to measles during the 2018 epidemics”, 27th Panhellenic Pulmonary Congress (Athens, 2018)

Publications In Evaluated Medical Journals

  • Zarkadi E, Bellou A, Polonyfi V, Karampitsakos T, Papageorgiou D, Lykouras D, Kaparianos A, Sampsonas F, Tsiamita M, Karkoulias K, Tzouvelekis A. Interesting CT image in a patient with cavitary lung lesion, Pneumon 2020
  • Karampitsakos T, Kalogeropoulos C, Tzilas V, Papaioannou O, Kazantzi A, Koukaki E, Katsaras M, Bouros E, Tsiri P, Tsirikos G, Zarkadi E, Ntoulias N, Sotiropoulou V, Eftymiou P, Chrysikos S, Malakounidou E, Sampsonas F, Bouros D, Tzouvelekis A. Safety and Effectiveness of Mycophenolate Mofetil in Interstitial Lung Deseases: Insights from a Machine Learning Radiographic Model, Respiration 2021
  • Karampitsakos T, Malakounidou E, Papaioannou O, Dimakopoulou V, Zarkadi E, Katsaras M, Tsiri P, Tsirikos G, Georgiopoulou V, Oikonnomou I, Davoulos C, Velissaris D, Sampsonas F, Marangos M, Akinosoglou K, Tzouvelekis A. Tocilizumab improves 28-days survival in hospitalized patients with severe COVID-19: an open label, prospective study, Repir Res. 2021